万孚生物多领域突破年赚5.62亿 慢病管理检测收入13.7亿增22%

Core Viewpoint - Wanfu Biotech has achieved initial success in its operational breakthrough, with significant revenue and profit growth in 2024, driven by favorable industry conditions and continuous product innovation [1][2]. Financial Performance - In 2024, the company reported total revenue of 3.065 billion yuan, a year-on-year increase of 10.85%, and a net profit of 562 million yuan, up 15.18% [2]. - The company's non-recurring net profit reached 497 million yuan, reflecting a growth of 19.9% [2]. - Total assets at the end of 2024 amounted to 7.155 billion yuan, increasing by 23.96%, while net assets grew by 22.99% to 5.554 billion yuan [2]. Business Segments - The chronic disease management testing segment showed the strongest performance, generating revenue of 1.369 billion yuan, a growth of 22.38% [1][2]. - Other business segments also experienced growth: infectious disease testing revenue was 1.042 billion yuan (up 9.50%), prenatal testing revenue was 294 million yuan (up 9.97%), and drug abuse testing revenue was 286 million yuan [2]. - International revenue reached 1.103 billion yuan, a significant increase of 43.23%, accounting for 55.42% of total revenue [2]. R&D Investment - Wanfu Biotech has invested heavily in R&D, with cumulative R&D expenditure reaching 2.346 billion yuan from 2019 to 2024 [3][4]. - In 2024, R&D investment was 438 million yuan, representing 14.30% of total revenue [4]. - The company holds a total of 642 product registration certificates, with 344 in China and 298 overseas, including 74 from the US FDA and 207 from the EU CE [3]. Innovation and Technology - The company has established multiple technology platforms, including immunochromatography, immunofluorescence, and molecular diagnostics, contributing to a diverse product line [3]. - In 2024, Wanfu Biotech obtained 55 new patents, including 39 invention patents, enhancing its competitive edge [4]. - The company employs over 700 R&D personnel and maintains a leading position in R&D intensity and team strength within the industry [4].